ArticlePublic health action2018
The California Multidrug-Resistant Tuberculosis Consult Service: a partnership of state and local programs.
Article in Public health action, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Updates on the Treatment of Drug-Susceptible and Drug-Resistant Tuberculosis: An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2025Guideline
- Outcomes and Treatment-limiting Adverse Events of Patients Receiving BPaL and BPaL-FQ in California.Open forum infectious diseases · 2026Article
- TB-related technical enquiries received at the Research Institute of Tuberculosis, Japan, during COVID-19.Public health action · 2024Article
- Costs of treating multidrug-resistant TB in California in 2022.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- TB-related technical enquiries received in Japan, 2017-2019.Public health action · 2022Article
- Low-Dose Linezolid for Treatment of Patients With Multidrug-Resistant Tuberculosis.Open forum infectious diseases · 2022Article
- Bedaquiline for multidrug-resistant tuberculosis and QTc prolongation in California.Journal of clinical tuberculosis and other mycobacterial diseases · 2021Article
- Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Tuberculosis Regional Training and Medical Consultation Centers in the United States: Characteristics, outcomes, and quality of medical consultations, June 1, 2010 - May 31, 2014.Journal of clinical tuberculosis and other mycobacterial diseases · 2019Article
- Tuberculosis in the United States: Medical Consultation Services Provided by 5 Tuberculosis Regional Training and Medical Consultation Centers, 2013-2017.Open forum infectious diseases · 2019Article
- Introduction and evaluation of multidrug-resistant tuberculosis supplemental surveillance in the United States.Journal of clinical tuberculosis and other mycobacterial diseases · 2019Article
- Tuberculosis-related technical enquiries received by a national level institution in Japan, 2014-2016.Public health action · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.